Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 161,901,639 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 91,101,164 shares Biodexa Pharmaceuticals plc (BDRX) rose 88.6% to $1.62 on volume of 87,7...
A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 54.8% to $0.2552 on volume of 35,107,796 shares Nikola Corporation (NKLA) rose 5.0% to $0.9546 on volume of 25,515,019 shares Biodexa Pharmaceuticals plc (BDRX) rose 83.9% to $1.58 on volume of 24,185,655 shar...
2024-03-28 09:59:09 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- Trump Media & Technology Group (NASDAQ:DJT), iBio, Inc. (NYSEAMERICAN: IBIO ), Xilio Therapeutics, Inc. (NASDAQ: XLO ) Biodexa Pharmaceuticals (NASDAQ: BDRX ), and Bre...
2024-03-28 09:20:29 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- This morning’s notable listings with recent news include Treasure & Shipwreck Recovery (OTCPK: BLIS ), Akebia Therapeutics, Inc. (NASDAQ: AKBA ), Avalo Therapeutics, Inc. (NASDAQ: AV...
2024-03-28 08:23:29 ET Gilead Sciences ( NASDAQ: GILD ) has signed an exclusive license deal to develop and commercialize Xilio Therapeutics’ ( NASDAQ: XLO ) XTX301, an investigational tumor-activated IL-12 program with potential to treat a broad range of cancers....
2024-03-28 08:14:16 ET More on Xilio Therapeutics Seeking Alpha’s Quant Rating on Xilio Therapeutics Historical earnings data for Xilio Therapeutics Financial information for Xilio Therapeutics Read the full article on Seeking Alpha For further...
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company’s promising research platform for tumor-activated bispecific and c...
— Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers — Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today an...
News, Short Squeeze, Breakout and More Instantly...
Xilio Therapeutics Inc. Company Name:
XLO Stock Symbol:
NASDAQ Market:
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quar...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and ...